MAZE vs RARE vs FOLD vs ACMR vs BEAM vs JPM

For growth investors, Beam Therapeutics Inc.

(BEAM) is the stronger pick with 120. 0% revenue growth year-over-year, versus -100. 0% for Maze Therapeutics, Inc. (MAZE). JPMorgan Chase & Co. (JPM) offers the better valuation at 15. 6x trailing P/E (14. 1x forward), making it the more compelling value choice. Analysts rate Maze Therapeutics, Inc. (MAZE) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, JPMorgan Chase & Co.

(JPM) is the cheapest at 15. 6x versus ACM Research, Inc. at 66. 9x. On forward P/E, JPMorgan Chase & Co. is actually cheaper at 14. 1x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: JPMorgan Chase & Co. wins at 1. 08x versus ACM Research, Inc. 's 1. 29x — a reasonable growth-adjusted valuation.

Over the past 5 years, ACM Research, Inc.

(ACMR) delivered a total return of +209. 9%, compared to -76. 4% for Ultragenyx Pharmaceutical Inc. (RARE). Over 10 years, the gap is even starker: ACMR returned +48. 0% versus RARE's -60. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Amicus Therapeutics, Inc.

(FOLD) is the lower-risk stock at 0. 50β versus ACM Research, Inc. 's 3. 40β — meaning ACMR is approximately 578% more volatile than FOLD relative to the S&P 500. On balance sheet safety, Maze Therapeutics, Inc. (MAZE) carries a lower debt/equity ratio of 7% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Beam Therapeutics Inc.

(BEAM) is pulling ahead at 120. 0% versus -100. 0% for Maze Therapeutics, Inc. (MAZE). On earnings-per-share growth, the picture is similar: Beam Therapeutics Inc. grew EPS 82. 3% year-over-year, compared to -40. 2% for Maze Therapeutics, Inc.. Over a 3-year CAGR, ACMR leads at 32. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

JPMorgan Chase & Co.

(JPM) is the more profitable company, earning 20. 4% net margin versus -612. 7% for Maze Therapeutics, Inc. — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus -670. 3% for MAZE. At the gross margin level — before operating expenses — MAZE leads at 92. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, JPMorgan Chase & Co. (JPM) is the more undervalued stock at a PEG of 1. 08x versus ACM Research, Inc. 's 1. 29x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, JPMorgan Chase & Co. (JPM) trades at 14. 1x forward P/E versus 46. 0x for ACM Research, Inc. — 31. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for MAZE: 162. 6% to $63. 25.

In this comparison, JPM (1.

9% yield), ACMR (0. 1% yield) pay a dividend. MAZE, RARE, FOLD, BEAM do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, JPMorgan Chase & Co.

(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 95), 1. 9% yield, +454. 4% 10Y return). ACM Research, Inc. (ACMR) carries a higher beta of 3. 40 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JPM: +454. 4%, ACMR: +48. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (MAZE (Healthcare) and RARE (Healthcare) and FOLD (Healthcare) and ACMR (Technology) and BEAM (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: MAZE is a small-cap quality compounder stock; RARE is a small-cap high-growth stock; FOLD is a small-cap high-growth stock; ACMR is a small-cap high-growth stock; BEAM is a small-cap high-growth stock; JPM is a large-cap deep-value stock. JPM pays a dividend while MAZE, RARE, FOLD, ACMR, BEAM do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.